Search

Your search keyword '"Harb, Jennifer"' showing total 3 results
Start Over Author "Harb, Jennifer" Topic sentinel lymph node biopsy
3 results on '"Harb, Jennifer"'

1. Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy.

Author

Doepker MP, Thompson ZJ, Harb JN, Messina JL, Puleo CA, Egan KM, Sarnaik AA, Gonzalez RJ, Sondak VK, and Zager JS

Subjects
Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Florida epidemiology, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Melanoma therapy, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Predictive Value of Tests, Prognosis, Skin Neoplasms therapy, Melanoma, Cutaneous Malignant, Lymph Nodes pathology, Melanoma mortality, Melanoma pathology, Sentinel Lymph Node Biopsy, Skin Neoplasms mortality, Skin Neoplasms pathology
Abstract

Introduction: Historically dermal melanoma (DM) has been labeled as either stage IIIB (in-transit) or stage IV (M1a) disease. We sought to investigate the natural history of DM and the utility and prognostic significance of sentinel lymph node biopsy (SLNB)., Methods: Patients with DM undergoing SLNB at a single center from 1998 to 2009 were identified., Results: Eighty-three patients met criteria, 10 (12%) patients had a positive SLNB. Of those, 5 (50%) recurred (all with distant disease). Twenty-one (29%) of the 73 SLNB negative patients recurred and of those, 15 (71%) developed distant metastases, whereas 6 (29%) developed local or regional recurrence, including two false-negative regional nodal recurrences. No in-transit recurrences were recorded. Five-year recurrence-free and disease-specific survival was significantly better for patients with a negative SLNB versus positive SLNB (56.8% vs. 22.2% P = 0.02, 81.1% vs. 61.0%, P = 0.05, respectively)., Conclusion: SLNB has prognostic significance for RFS and DSS, and should be utilized in the management of DM based on a >10% yield and low false-negative rate. Our data demonstrate patients with DM do not recur in an in-transit fashion, which along with the survival outcomes suggest the behavior of DM is consistent with primary cutaneous melanoma of similar thickness rather than an isolated in-transit or distant dermal metastasis from a regressed cutaneous primary., (© 2015 Wiley Periodicals, Inc.)

Published
2016
Full Text
View/download PDF

2. Is a Wider Margin (2 cm vs. 1 cm) for a 1.01–2.0 mm Melanoma Necessary?

Author

Doepker, Matthew P, Thompson, Zachary J, Fisher, Kate J, Yamamoto, Maki, Nethers, Kevin W, Harb, Jennifer N, Applebaum, Matthew A, Gonzalez, Ricardo J, Sarnaik, Amod A, Messina, Jane L, Sondak, Vernon K, and Zager, Jonathan S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Dental/Oral and Craniofacial Disease, Cancer, Rare Diseases, Adolescent, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Lymph Node Excision, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Skin Neoplasms, Survival Rate, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThe current NCCN recommendation for resection margins in patients with melanomas between 1.01 and 2 mm deep is a 1-2 cm radial margin. We sought to determine whether margin width had an impact on local recurrence (LR), disease-specific survival (DSS), and type of wound closure.MethodsMelanomas measuring 1.01-2.0 mm were evaluated at a single institution between 2008 and 2013. All patients had a 1 or 2 cm margin.ResultsWe identified 965 patients who had a 1 cm (n = 302, 31.3 %) or 2 cm margin (n = 663, 68.7 %). Median age was 64 years, and 592 (61.3 %) were male; 32.5 and 48.7 % of head and neck and extremity patients had a 1 cm margin versus 18.9 % of trunk patients (p

Published
2016

3. Dermal Melanoma: A Report on Prognosis, Outcomes, and the Utility of Sentinel Lymph Node Biopsy

Author

DOEPKER, MATTHEW P., THOMPSON, ZACHARY J., HARB, JENNIFER N., MESSINA, JANE L., PULEO, CHRISTOPHER A., EGAN, KATHLEEN M., SARNAIK, AMOD A., GONZALEZ, RICARDO J., SONDAK, VERNON K., and ZAGER, JONATHAN S.

Subjects
Adult, Aged, 80 and over, Male, Skin Neoplasms, Sentinel Lymph Node Biopsy, Kaplan-Meier Estimate, Middle Aged, Prognosis, Article, Disease-Free Survival, Predictive Value of Tests, Lymphatic Metastasis, Florida, Humans, Female, Lymph Nodes, Neoplasm Recurrence, Local, Melanoma, Aged, Neoplasm Staging
Abstract

Historically dermal melanoma (DM) has been labeled as either stage IIIB (in-transit) or stage IV (M1a) disease. We sought to investigate the natural history of DM and the utility and prognostic significance of sentinel lymph node biopsy (SLNB).Patients with DM undergoing SLNB at a single center from 1998 to 2009 were identified.Eighty-three patients met criteria, 10 (12%) patients had a positive SLNB. Of those, 5 (50%) recurred (all with distant disease). Twenty-one (29%) of the 73 SLNB negative patients recurred and of those, 15 (71%) developed distant metastases, whereas 6 (29%) developed local or regional recurrence, including two false-negative regional nodal recurrences. No in-transit recurrences were recorded. Five-year recurrence-free and disease-specific survival was significantly better for patients with a negative SLNB versus positive SLNB (56.8% vs. 22.2% P = 0.02, 81.1% vs. 61.0%, P = 0.05, respectively).SLNB has prognostic significance for RFS and DSS, and should be utilized in the management of DM based on a10% yield and low false-negative rate. Our data demonstrate patients with DM do not recur in an in-transit fashion, which along with the survival outcomes suggest the behavior of DM is consistent with primary cutaneous melanoma of similar thickness rather than an isolated in-transit or distant dermal metastasis from a regressed cutaneous primary.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results